Premium Company Profile: Cubist Pharmaceuticals

Summary

Cubist Pharmaceuticals is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. Cubicin, Cubist's major product, is approved for multiple indications in many countries. In the US, Cubicin is being marketed for the treatment of complicated skin structure infections (cSSI).

Scope

• Contains corporate strategy, value chain presence and SWOT Analysis
• Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
• Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

Cubist has one marketed product, Cubicin, an antibiotic from a class of antiinfectives called lipopeptides, for the treatment of complicated skin and skin structure infections, and for other blood-stream infections. The company's research and development programs include lipopeptide programs.

Cubist has research collaboration with Ilypsa to develop ILY103, a non-antibiotic, toxin binder therapy for the treatment of clostridium difficile associated diarrhea which is in preclinical trials.

Cubist derives its revenues from the product sales of Cubicin and other revenues which includes license agreements revenues, Small Business Innovation Research (SBIR) and grant revenue. Cubist's total revenues increased at a CAGR of 103% during 2002-2006, from $11 million in 2002 to $195 million in 2006.

Reasons to Purchase

• Access all the important information and analysis on the company in a single report
• Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
• Gain access to company's adjusted five year financial data along with key ratios and market capitalization

Content